Renovaro Inc
RENB0.251USD
-0.007-2.86%
Market hours （ET）Quotes delayed by 15 min
40.78MMarket Cap
LossP/E TTM
More Details of Renovaro Inc Company
Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Company Info
Ticker SymbolRENB
Company nameRenovaro Inc
IPO dateNov 18, 2014
CEOMr. David Weinstein
Number of employees25
Security typeOrdinary Share
Fiscal year-endNov 18
Address2080 Century Park East,
CityLOS ANGELES
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code90067
Phone14539179840
Websitehttps://renovarobio.com/
Ticker SymbolRENB
IPO dateNov 18, 2014
CEOMr. David Weinstein
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Maurice Van Tilburg
Mr. Maurice Van Tilburg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President
Executive Vice President
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Maurice Van Tilburg
Mr. Maurice Van Tilburg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President
Executive Vice President
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
PasecoApS
11.69%
RS Group ApS
7.29%
Gumrukcu (Serhat)
5.42%
BlackRock Institutional Trust Company, N.A.
2.95%
The Vanguard Group, Inc.
2.45%
Other
70.20%
Shareholders
Shareholders
Proportion
PasecoApS
11.69%
RS Group ApS
7.29%
Gumrukcu (Serhat)
5.42%
BlackRock Institutional Trust Company, N.A.
2.95%
The Vanguard Group, Inc.
2.45%
Other
70.20%
Shareholder Types
Shareholders
Proportion
Corporation
36.84%
Individual Investor
10.44%
Investment Advisor
8.61%
Investment Advisor/Hedge Fund
3.55%
Research Firm
0.41%
Hedge Fund
0.13%
Bank and Trust
0.07%
Pension Fund
0.04%
Other
39.92%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
157
103.42M
47.15%
+42.61M
2025Q1
161
103.48M
60.94%
+42.30M
2024Q4
155
103.71M
63.86%
+49.62M
2024Q3
149
51.49M
35.21%
-1.80M
2024Q2
151
51.88M
36.43%
+6.39M
2024Q1
154
44.98M
32.23%
+3.81M
2023Q4
151
44.01M
67.51%
+217.77K
2023Q3
146
41.12M
71.08%
+1.11M
2023Q2
147
41.48M
71.99%
+3.87M
2023Q1
143
36.45M
65.90%
-482.82K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
PasecoApS
12.62M
7.33%
+8.16M
+182.78%
Oct 17, 2024
RS Group ApS
13.60M
7.9%
+468.70K
+3.57%
Oct 17, 2024
Gumrukcu (Serhat)
12.53M
7.28%
--
--
Apr 10, 2025
BlackRock Institutional Trust Company, N.A.
6.81M
3.96%
+847.01K
+14.20%
Mar 31, 2025
The Vanguard Group, Inc.
5.66M
3.29%
-58.46K
-1.02%
Mar 31, 2025
William (Anderson Wittekind)
4.77M
2.77%
--
--
Apr 10, 2025
Geode Capital Management, L.L.C.
2.37M
1.38%
+35.02K
+1.50%
Mar 31, 2025
State Street Global Advisors (US)
2.00M
1.16%
-61.67K
-2.99%
Mar 31, 2025
Weinstein (David Hershel)
250.00K
0.15%
+250.00K
--
Oct 17, 2024
Weird Science LLC
840.32K
0.49%
--
--
Apr 10, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
